Cardiometabolic health in bipolar disorder

Psychiatric Annals

Volumn 42, Issue 5, 2012, Pages 179-183

  Kemp, David E ^a   Fan, Jinbo ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863752291     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20120507-05     Document Type: Article

References (46)

1. Kemp DE, Gao K, Ganocy SJ, et al. Medical and substance use comorbidity in bipolar disorder. J Affect Disord. 2009;116:64-69.
2. Perron BE, Howard MO, Nienhuis JK, et al. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2009;70:1407-1415.
3. Calkin C, van de Velde C, Ruzickova M. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord. 2009;11(6):650-656.
4. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JRC. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 2010;12:404-413.
5. Thompson WK, Kupfer DJ, Fagiolini A, et al. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry. 2006;67(5):783-788.
6. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord. 2010;126:366-387.
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
8. Correll CU, Frederickson AM, Kane JM, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10(7):788-797.
9. Druss BG, Zhao L, Von Esenwein S, et al. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med Care. 2011;49(6):599-604.
10. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68(2-3):167-181.
11. Fiedorowicz JG, Solomon DA, Endicott J, et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med. 2009;71(6):598-606.
12. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a Correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160:112-117.
13. Kemp DE, Karayal ON, Calabrese JR, et al. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol. 2012;22(2):123-131.
14. Bond DJ, Lang DJ, Noronha MM, et al. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry. 70(4):381-387.
15. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as "metabolic syndrome type II"? Ann Clin Psychiatry. 2007;19(4):257-264.
16. Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70:1078-1090.
17. Zandi PP, Judy JT: The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am. 2010;33:181-224.
18. Lett TA, Wallace TJ, Chowdhury NI, et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;17(3):242-266.
19. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359(9323):2086-2087.
20. Altshuler D, Daly M, Kruglyak L. Guilt by association. Nat Genet. 2000;26(2):135-137.
21. Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996;57(10):470-484.
22. Festa A, D'Agostino R, Jr., Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-47.
23. Zeman M, Jirak R, Jachymova M, et al. Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. Neuro Endocrinol Lett. 2009;30(3):387-395.
24. Lawson EA, Miller KK, Blum JI, et al. Leptin levels are associated with decreased depressive symptoms in women across the weight spectrum, independent of body fat. Clin Endocrinol (Oxf). 2012;76(4):520-525.
25. Lehto SM, Huotari A, Niskanen L, et al. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand. 2010;121(3):209-215.
26. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360(9326):57-58.
27. McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep. 2009;9(1):51-59.
28. Robertson RP, Harmon J, Tran PO, et al. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53(Suppl 1):S119-124.
29. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry. 2003;54(3):200-207.
30. Brietzke E, Kapczinski F, Grassi-Oliveira R, et al. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother. 2011;11(7):1017-1028.
31. Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008;40(5):638-645.
32. Sklar P, Smoller JW, Fan J, et al. Whole-genome association study of bipolar disorder. Mol Psychiatry. 2008;13:558-569.
33. Thorleifsson G, Walters GB, Gudbjartsson DF, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet. 2009;41(1):18-24.
34. Fan J, Sklar P. Genetics of bipolar disorder: focus on BDNF Val66Met polymorphism. Novartis Foundation Symposium. 2008;289:60-72; discussion 72-63, 87-93.
35. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1-93.
36. Consensus Development Conference on Insulin Resistance. 5-6 November 1997. American Diabetes Association. Diabetes Care. 1998;21(2):310-314.
37. Fan X, Liu EY, Hoffman VP, Potts AJ, Sharma B, Henderson DC. Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia. J Clin Psychiatry. 2011;72(6):806-812.
38. McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, Kemp DE. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012;24(1):69-81.
39. Sylvia LG, Nierenberg AA, Stange JP, et al. Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder. J Psychiatr Pract. 2011;17(3):224-232.
40. McNay EC, Recknagel AK. Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem. 2011;96(3):432-442.
41. Francis GJ, Martinez JA, Liu WQ, et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain. 2008;131(Pt 12):3311-3334.
42. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29-38.
43. Sadaghiani MS, Javadi-Paydar M, Gharedaghi MH, et al. Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Behav Brain Res. 2011, 224(2):336-343.
44. Kemp DE, Ismail-Beigi F, Ganocy SJ, et al. Use of insulin sensitizers for the treatment of major depressive disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord. 2012;136(3):1164-1173.
45. Rasgon NL, Kenna HA, Williams KE, et al. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Scientific World J. 2010;10:321-328.
46. Berk M, Dean O, Cotton SM, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord. 2011;135(1-3):389-394.